- Home
- BON vs BFRI Comparison
BON vs BFRI Comparison
Compare BON & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BON
- BFRI
- Stock Information
- Founded
- BON 2006
- BFRI 1997
- Country
- BON China
- BFRI United States
- Employees
- BON N/A
- BFRI N/A
- Industry
- BON Medicinal Chemicals and Botanical Products
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- BON Health Care
- BFRI Health Care
- Exchange
- BON Nasdaq
- BFRI Nasdaq
- Market Cap
- BON 6.1M
- BFRI 6.2M
- IPO Year
- BON 2021
- BFRI 2021
- Fundamental
- Price
- BON $1.49
- BFRI $1.01
- Analyst Decision
- BON
- BFRI Strong Buy
- Analyst Count
- BON 0
- BFRI 1
- Target Price
- BON N/A
- BFRI $7.00
- AVG Volume (30 Days)
- BON 35.8K
- BFRI 990.2K
- Earning Date
- BON 02-07-2025
- BFRI 11-13-2024
- Dividend Yield
- BON N/A
- BFRI N/A
- EPS Growth
- BON N/A
- BFRI N/A
- EPS
- BON 2.22
- BFRI N/A
- Revenue
- BON $25,555,939.00
- BFRI $35,358,000.00
- Revenue This Year
- BON $47.04
- BFRI $17.69
- Revenue Next Year
- BON $77.63
- BFRI $19.71
- P/E Ratio
- BON $0.66
- BFRI N/A
- Revenue Growth
- BON N/A
- BFRI 5.17
- 52 Week Low
- BON $1.23
- BFRI $0.61
- 52 Week High
- BON $6.00
- BFRI $3.90
- Technical
- Relative Strength Index (RSI)
- BON 45.41
- BFRI 51.26
- Support Level
- BON $1.37
- BFRI $0.94
- Resistance Level
- BON $1.75
- BFRI $1.06
- Average True Range (ATR)
- BON 0.16
- BFRI 0.13
- MACD
- BON -0.02
- BFRI -0.01
- Stochastic Oscillator
- BON 21.00
- BFRI 23.51
About BON Bon Natural Life Limited
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. The company has its geographic presence in PRC and in Overseas. The company derives maximum revenue from perfumes and fragrance products.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.